Electroacupuncture may reduce hot flashes among breast cancer survivors
the ONA take:
Electroacupuncture may be more effective and safer than gabapentin for managing hot flashes among breast cancer survivors, according to a new study published online ahead of print in the Journal of Clinical Oncology.
For the study, researchers from the University of Pennsylvania Perelman School of Medicine in Philadelphia, PA, and colleagues sought to compare the effects of electroacupuncture with gabapentin for hot flashes among breast cancer survivors.
Researchers enrolled 120 breast cancer survivors who were experiencing bothersome hot flashes at least twice per day day. Participants were randomly assigned to receive 8 weeks of electroacupuncture or gabapentin once daily with placebo acupuncture or pills.
Results showed that by week 8, patients in the electroacupuncture group experienced the greatest reduction in hot flash composite score, followed by placebo electroacupuncture, gabapentin, and placebo pills (P≤0.001).
In regard to safety, patients in the gabapentin group experienced the greatest amount of treatment-related adverse events, followed by placebo pills, electroacupuncture, and placebo electroacupuncture (P=0.005).
By week 24, electroacupuncture was still the most effective treatment for reducing hot flash composite score. The authors note that these findings need to be confirmed in a larger randomized controlled trial with long-term follow-up.
Electroacupuncture may be more effective and safer than gabapentin for managing hot flashes among breast cancer survivors.
Sign Up for Free e-newsletters
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|